J&J’s IMAAVY 30 mg/kg Dose Triples Placebo Hemoglobin Response, Gains FDA Priority Review
JNJ•J&J’s Phase 2/3 ENERGY trial showed 30 mg/kg IMAAVY patients achieving 2 g/dL hemoglobin rises and ≥10 g/dL concentration by Week 24 at three times placebo rate. It drove ≥1 g/dL gains in one week, reduced fatigue and steroid use, had a favorable safety profile, and supports FDA Priority Review for rare anemia therapy.
1. Phase 2/3 ENERGY Trial Results
Johnson & Johnson’s ENERGY study evaluated IMAAVY in warm autoimmune hemolytic anemia, comparing a 30 mg/kg dose to placebo over 24 weeks. Two-thirds of patients on IMAAVY achieved a durable ≥2 g/dL hemoglobin increase with concentrations ≥10 g/dL—three times the placebo response—and saw ≥1 g/dL gains by Week 1, alongside reduced fatigue and steroid reliance.
2. Primary Endpoint and Clinical Benefits
The trial’s primary endpoint required a ≥2 g/dL hemoglobin increase from baseline and a concentration of at least 10 g/dL at three visits over a 28-day period starting by Week 16, without rescue therapy or background medication changes. Patients also experienced reduced fatigue and lower steroid requirements, indicating meaningful clinical benefits.
3. Consistent Safety Profile
IMAAVY’s safety profile in hemolytic anemia patients mirrored its established use in myasthenia gravis, with peripheral edema, diarrhea and fever reported in at least 10% of participants. No new safety signals emerged, supporting the therapy’s tolerability in this patient population.
4. Regulatory Progress and Market Outlook
Johnson & Johnson filed a supplemental Biologics License Application for IMAAVY in warm autoimmune hemolytic anemia and secured FDA Priority Review. With no approved treatments currently available, the therapy could address a significant unmet need in a rare disease market.
